Previous Close | 39.34 |
Open | 39.37 |
Bid | 39.64 x 48300 |
Ask | 39.65 x 51100 |
Day's Range | 39.18 - 39.74 |
52 Week Range | 33.75 - 44.81 |
Volume | |
Avg. Volume | 623,161 |
Market Cap | 8.801B |
Beta (5Y Monthly) | 0.41 |
PE Ratio (TTM) | 28.11 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.18 (2.94%) |
Ex-Dividend Date | Jan 30, 2024 |
1y Target Est | N/A |
QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management // Growing global presence: Over 4,000 QIAstat-Dx instruments for reliable, fast and cost‑effective diagnosis of complex syndromes placed worldwide by the end of 2023Venlo, the Netherlands, March 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: Q
Joint educational initiative to focus on Interferon Gamma Release Assay (IGRA) benefits for healthcare providers // Updated U.S. CDC guidelines mandate IGRA testing for individuals aged 2 and older from high‑TB incidence countries, as part of U.S. immigrant visa medical exam // QIAGEN to host global, CPD-accredited event on March 21, just before World TB Day, focusing on TB infection screening, preventive therapy and challenges of high-risk groupsGermantown, Maryland, and Venlo, the Netherlands,
Venlo, the Netherlands, March 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here. QIAGEN will provide printed copies of the 2023 Annual Report to shareholders free of charge upon request. To obtain a p